# Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis

> **NCT01261403** · PHASE2 · TERMINATED · sponsor: **Celularity Incorporated** · enrollment: 26 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** PDA001
- **DRUG:** Vehicle Controlled Placebo

## Key facts

- **NCT ID:** NCT01261403
- **Lead sponsor:** Celularity Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2012-02
- **Final completion:** 2013-09
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Enrollment terminated pending additional Phase 1 data
- **Last updated:** 2020-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01261403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01261403, "Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01261403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*